Vera Therapeutics Inc (VERA NASDAQ) stock market data APIs
$23.1574
0.49(2.1%)
as of July 1, 2025
Try our APIs with
free plan!
Vera Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with serious immunological diseases. The company's lead product candidate consists of atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN). It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Prev. Close
23.1574
Open
23.6513
High
23.7803
Low
22.8319
52 wk Range
18.53-51.61
Market Cap
1 467 M
Shares Outstanding
63 774 K
EPS
-0.8119
Beta
1.128
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Vera Therapeutics Inc data using free add-ons & libraries
Get Vera Therapeutics Inc Fundamental Data
Vera Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -193 072 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-15
- EPS/Forecast: -0.7795
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Vera Therapeutics Inc News
New
Thursday 6/26 Insider Buying Report: VERA, GMRE
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their har...
Insider Purchase: Director at $VERA Buys 139,595 Shares
PATRICK G ENRIGHT, a director at $VERA, bought 139,595 shares of the company on 06-23-2025 for an estimated $2,913,110. This trade was reported by Quiver Quantitative using data from a recent SEC fili...
Vera Therapeutics director Enright buys shares worth $5.2m
Director Patrick G. Enright of Vera Therapeutics , Inc. (NASDAQ:VERA) recently purchased shares of Class A Common Stock. On June 23 and 24, 2025, Enright acquired a total of 250,690 shares at prices ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of no...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
